Hematologic Malignancy
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
CI-CAN-00000765Explore in graph →
Hematologic298 active trials6 approved drugs47 evidence items
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00000765Explore in graph →
Clinical trials
1,406 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (273)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02029443 | ACP-196 (Acalabrutinib), a Novel Bruton Tyrosine Kinase (BTK) Inhibitor, for Treatment of Chronic Lymphocytic Leukemia, Richter's Syndrome or Prolymphocytic Leukemia | active not recruiting | Phase 1 / Phase 2 | 306 | Acerta Pharma BVINDUSTRY | 3 | May 5, 2026 | clinicaltrials |
| NCT03035331 | Dendritic Cell Therapy, Cryosurgery, and Pembrolizumab in Treating Patients With Non-Hodgkin Lymphoma | completed | Phase 1 / Phase 2 | 11 | Mayo ClinicOTHER | 1 | May 4, 2026 | clinicaltrials |
| NCT01500733 | PCI-32765 for Special Cases of Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | active not recruiting | Phase 2 | 86 | National Heart, Lung, and Blood Institute (NHLBI)NIH | 1 | Apr 28, 2026 | clinicaltrials |
| NCT06839053 | Sonrotoclax, Rituximab, and Zanubrutinib in Treating Participants With Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, and Mantle Cell Lymphoma | recruiting | Phase 2 | 30 | Fred Hutchinson Cancer CenterOTHER | 1 | Apr 22, 2026 | clinicaltrials |
| NCT01384513 | A Two-Step Approach to Reduced Intensity Bone Marrow Transplant for Patients With Hematological Malignancies | completed | Phase 2 | 40 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityOTHER | 1 | Apr 15, 2026 | clinicaltrials |
| NCT02514083 | A Phase II Study Using Ibrutinib and Short-Course Fludarabine in Treatment-Naive CLL | active not recruiting | Phase 2 | 29 | National Heart, Lung, and Blood Institute (NHLBI)NIH | 1 | Apr 14, 2026 | clinicaltrials |
| NCT01589302 | PCI-32765 (Ibrutinib) in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or B-cell Prolymphocytic Leukemia | active not recruiting | Phase 2 | 154 | Kami Maddocks, MDOTHER | 1 | Apr 13, 2026 | clinicaltrials |
| NCT04560322 | Venetoclax-Obinutuzumab +/- Acalabrutinib in R/R CLL | recruiting | Phase 2 | 40 | Massachusetts General HospitalOTHER | 1 | Apr 13, 2026 | clinicaltrials |
| NCT05183854 | Pneumococcal Pneumonia Vaccine Series (PCV20 and PPSV23) in Patients With Chronic Lymphocytic Leukemia Associated Immunodeficiency, PROTECT CLL Trial | recruiting | Phase 2 | 61 | University of UtahOTHER | 1 | Apr 9, 2026 | clinicaltrials |
| NCT02518555 | Ibrutinib as an Immune Modulating Agent for Patients With Asymptomatic, High-risk CLL/SLL Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | completed | Phase 2 | 42 | Jennifer WoyachOTHER | 1 | Apr 6, 2026 | clinicaltrials |
| NCT03467867 | A Study of Venetoclax and Rituximab/Hyaluronidase Human in Relapsed/Refractory CLL | active not recruiting | Phase 2 | 25 | Georgetown UniversityOTHER | 1 | Apr 6, 2026 | clinicaltrials |
| NCT01723839 | Phase II Protocol for CLL With Fludarabine and Cyclophosphamide With Rituximab (FCR) Plus Lenalidomide(FCR) | completed | Phase 2 | 21 | Hackensack Meridian HealthOTHER | 1 | Apr 3, 2026 | clinicaltrials |
| NCT05147467 | Study of APG-2575 in Patients With Relapsed/Refractory CLL/SLL | recruiting | Phase 2 | 75 | Ascentage Pharma Group Inc.INDUSTRY | 1 | Mar 27, 2026 | clinicaltrials |
| NCT05702853 | Metabolically Fit CD19 CAR T-cell Therapy With CD34 Selection in Patients With CD19+ Relapsed/Refractory NHL, CLL/SLL | recruiting | Phase 1 / Phase 2 | 27 | Medical University of South CarolinaOTHER | 1 | Mar 27, 2026 | clinicaltrials |
| NCT02717611 | A Study of ACP-196 (Acalabrutinib) in Subjects With Relapsed/Refractory CLL and Intolerant of Ibrutinib Therapy | active not recruiting | Phase 2 | 60 | Acerta Pharma BVINDUSTRY | 6 | Mar 25, 2026 | clinicaltrials |
| NCT05388006 | Acalabrutinib, Venetoclax and Durvalumab for the Treatment of Richter Transformation From Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | recruiting | Phase 2 | 27 | Mayo ClinicOTHER | 1 | Mar 25, 2026 | clinicaltrials |
| NCT03534323 | Duvelisib and Venetoclax in Relapsed or Refractory CLL or SLL or RS | active not recruiting | Phase 1 / Phase 2 | 55 | Dana-Farber Cancer InstituteOTHER | 1 | Mar 23, 2026 | clinicaltrials |
| NCT02952508 | Study of Iopofosine I-131 (CLR 131) in Select B-Cell Malignancies (CLOVER-1) With Expansion in Waldenstrom(CLOVER-WaM) | active not recruiting | Phase 2 | 120 | Cellectar Biosciences, Inc.INDUSTRY | 11 | Mar 18, 2026 | clinicaltrials |
| NCT04904588 | HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide(ACCESS) | active not recruiting | Phase 2 | 300 | Center for International Blood and Marrow Transplant ResearchNETWORK | 1 | Mar 18, 2026 | clinicaltrials |
| NCT02135133 | A Study of Idelalisib (GS1101, CAL101) + Ofatumumab in Previously Untreated CLL/SLL | completed | Phase 2 | 27 | Dana-Farber Cancer InstituteOTHER | 1 | Mar 17, 2026 | clinicaltrials |
| NCT05478512 | Front-line VenObi Combination Followed by Ven or VenZan Combination in Patients With Residual Disease: a MRD Tailored Treatment for Young Patients With High-risk CLL(VIS) | active not recruiting | Phase 2 | 78 | Gruppo Italiano Malattie EMatologiche dell'AdultoOTHER | 1 | Mar 17, 2026 | clinicaltrials |
| NCT06859424 | A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation(ACCELERATE) | recruiting | Phase 2 | 358 | Center for International Blood and Marrow Transplant ResearchNETWORK | 1 | Mar 17, 2026 | clinicaltrials |
| NCT07218510 | Venetoclax and Obinutuzumab Followed by Epcoritamab for the Treatment of Untreated Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma, LonGEVity Trial | recruiting | Phase 2 | 33 | City of Hope Medical CenterOTHER | 1 | Mar 13, 2026 | clinicaltrials |
| NCT02213913 | Lenalidomide and Combination Chemotherapy (DA-EPOCH-R) in Treating Patients With MYC-Associated B-Cell Lymphomas | completed | Phase 1 / Phase 2 | 55 | University of ChicagoOTHER | 1 | Mar 11, 2026 | clinicaltrials |
| NCT06059391 | CMV-MVA Triplex Vaccination in HLA-Matched Related Stem Cell Donors for the Prevention of CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplant | recruiting | Phase 2 | 216 | City of Hope Medical CenterOTHER | 1 | Mar 10, 2026 | clinicaltrials |
| NCT05479994 | Study of BGB-11417 in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | active not recruiting | Phase 2 | 100 | BeiGeneINDUSTRY | 1 | Mar 4, 2026 | clinicaltrials |
| NCT05873712 | Zanubrutinib and Lisocabtagene Maraleucel for the Treatment of Richter's Syndrome | recruiting | Phase 2 | 24 | Aseel AlsouqiOTHER | 1 | Mar 3, 2026 | clinicaltrials |
| NCT03514017 | Ibrutinib and PD-1 Blockade in High Risk Lymphocytic Leukemia | terminated | Phase 2 | 5 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Mar 2, 2026 | clinicaltrials |
| NCT03609593 | Bendamustine/Rituximab Followed by Venetoclax and Rituximab for Treatment of Chronic Lymphocytic Leukemia | completed | Phase 2 | 42 | Nicole LamannaOTHER | 1 | Feb 25, 2026 | clinicaltrials |
| NCT04624633 | Acalabrutinib, Umbralisib, and Ublituximab (AU2) In Relapsed and Untreated CLL | active not recruiting | Phase 2 | 29 | Jennifer R. Brown, MD, PhDOTHER | 1 | Feb 25, 2026 | clinicaltrials |
| NCT04186520 | CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell Malignancies | recruiting | Phase 1 / Phase 2 | 100 | Medical College of WisconsinOTHER | 1 | Feb 23, 2026 | clinicaltrials |
| NCT04282018 | Study of BGB-10188 as Monotherapy, and in Combination With Zanubrutinib, and Tislelizumab | completed | Phase 1 / Phase 2 | 97 | BeiGeneINDUSTRY | 2 | Feb 20, 2026 | clinicaltrials |
| NCT05336812 | Acalabrutinib in Combination With Venetoclax or Obinutuzumab for the Treatment of Treatment-naive Chronic Lymphocytic Leukemia | recruiting | Phase 2 | 52 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Feb 19, 2026 | clinicaltrials |
| NCT06466122 | Pirtobrutinib (LOXO-305) and Venetoclax for the Treatment of Patients With CLL or SLL Resistant to Covalent BTKi | recruiting | Phase 2 | 30 | Kerry RogersOTHER | 1 | Feb 19, 2026 | clinicaltrials |
| NCT02158091 | A Phase 1b/2 Study of IPI-145 Plus FCR in Previously Untreated, Younger Patients With CLL | active not recruiting | Phase 1 / Phase 2 | 32 | Dana-Farber Cancer InstituteOTHER | 1 | Feb 13, 2026 | clinicaltrials |
| NCT03580928 | Acalabrutinib, Venetoclax, and Obinutuzumab for Initial Therapy of CLL(AVO) | active not recruiting | Phase 2 | 72 | Dana-Farber Cancer InstituteOTHER | 1 | Feb 13, 2026 | clinicaltrials |
| NCT05677919 | Pirtobrutinib and Venetoclax With MRD Detection for Previously Untreated Chronic Lymphocytic Leukemia | active not recruiting | Phase 2 | 72 | Mayo ClinicOTHER | 1 | Feb 12, 2026 | clinicaltrials |
| NCT06644183 | Roginolisib (IOA-244) With Venetoclax and Rituximab for Refractory/Relapsed Chronic Lymphocytic Leukemia (CLL) | recruiting | Phase 1 / Phase 2 | 64 | Jennifer R. Brown, MD, PhDOTHER | 1 | Feb 11, 2026 | clinicaltrials |
| NCT04895436 | Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax With Intravenous (IV) Obinutuzumab in Adult Participants With Recurring Chronic Lymphocytic Leukemia (CLL)(ReVenG) | recruiting | Phase 2 | 75 | AbbVieINDUSTRY | 11 | Feb 9, 2026 | clinicaltrials |
| NCT03513562 | Venetoclax and Ibrutinib in Treating in Participants With Chronic Lymphocytic Leukemia and Ibrutinib Resistance Mutations | active not recruiting | Phase 2 | 28 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Feb 6, 2026 | clinicaltrials |
| NCT04809467 | A Study Evaluating Safety, PK, and Efficacy of Tafasitamab and Parsaclisib in Participants With Relapsed/Refractory Non Hodgkin Lymphoma (R/R NHL) or Chronic Lymphocytic Leukemia (CLL)(topMIND) | terminated | Phase 1 / Phase 2 | 54 | Incyte CorporationINDUSTRY | 7 | Feb 4, 2026 | clinicaltrials |
| NCT03204188 | Ibrutinib, Fludarabine, and Pembrolizumab in High-Risk or Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | completed | Phase 2 | 15 | National Heart, Lung, and Blood Institute (NHLBI)NIH | 1 | Jan 30, 2026 | clinicaltrials |
| NCT04116437 | Zanubrutinib (BGB-3111) in Participants With Previously Treated B-Cell Lymphoma Intolerant of Prior Bruton Tyrosine Kinase Inhibitor (BTKi) Treatment | completed | Phase 2 | 96 | BeiGeneINDUSTRY | 1 | Jan 28, 2026 | clinicaltrials |
| NCT03740529 | A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHL | completed | Phase 1 / Phase 2 | 803 | Loxo Oncology, Inc.INDUSTRY | 10 | Jan 27, 2026 | clinicaltrials |
| NCT06333262 | Fixed Duration Pirtobrutinib and Obinutuzumab in Chronic Lymphocytic Leukemia | recruiting | Phase 2 | 60 | Inhye AhnOTHER | 1 | Jan 21, 2026 | clinicaltrials |
| NCT05417165 | Anti-pneumococcal Vaccine Strategy in Patients With Chronic Lymphocytic Leukemia | recruiting | Phase 2 | 80 | Seema BhatOTHER | 1 | Jan 7, 2026 | clinicaltrials |
| NCT06043674 | Phase 2 Study of Glofitamab Monotherapy & With Polatuzumab Vedotin, Pirtobrutinib, or Atezolizumab in Richter's Transformation | recruiting | Phase 2 | 70 | Christine RyanOTHER | 1 | Jan 7, 2026 | clinicaltrials |
| NCT04163718 | TGR-1202 (Umbralisib) in Treatment Naïve Patients With Chronic Lymphocytic Leukemia (CLL) | terminated | Phase 2 | 12 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Jan 6, 2026 | clinicaltrials |
| NCT07014917 | Intermittent Versus Continuous Venetoclax With Acalabrutinib for CLL/SLL(ESR-23-22182) | recruiting | Phase 2 | 62 | Zulfa OmerOTHER | 1 | Jan 6, 2026 | clinicaltrials |
| NCT07108998 | Study of Epcoritamab as a Consolidation Therapy in CLL/SLL | recruiting | Phase 2 | 22 | Zulfa OmerOTHER | 1 | Jan 6, 2026 | clinicaltrials |
Data updated 22 days agoSource updated May 5, 2026source: clinicaltrials